Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
Status:
RECRUITING
Trial end date:
2026-01-08
Target enrollment:
Participant gender:
Summary
The primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects. Secondary objectives of study are as follows: To estimate the PK parameters of single-ascending SC doses of HC022 in healthy subjectsTo evaluate the immunogenicity of HC022 administered to healthy subjects.